A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Recruiting
99 years or below
All
Phase 2
15 participants needed
1 Location

Brief description of study

This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian cancer, however no drug has been approved for maintenance therapy in recurrent endometrial cancer by the FDA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: endometrial cancer
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832490

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.